Oramed Pharmaceuticals (ORMP) EPS (Weighted Average and Diluted) (2021 - 2026)
Oramed Pharmaceuticals (ORMP) reported EPS (Weighted Average and Diluted) of $0.91 for Q1 2026, up 578.95% on a YoY basis from $0.13 in Q1 2025, and up 279.17% quarter-over-quarter from $0.24 in Q4 2025.
Oramed Pharmaceuticals (ORMP) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Oramed Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $0.91 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 578.95% year-over-year to $0.91; the trailing twelve-month figure through Mar 2026 stood at $2.59 (up 464.79% YoY), and the FY2025 full-year result was $1.5, up 412.5% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.91, up from $0.24 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.13 in Q3 2025, with the low at -$0.48 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.06 across 5 years, with a median of -$0.08 in 2023.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) jumped 833.33% — and 2025, when it sank 575.0%.
- Oramed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.3 in 2022, then soared by 210.3% to $0.33 in 2023, then slumped by 178.79% to -$0.26 in 2024, then soared by 192.31% to $0.24 in 2025, then soared by 279.17% to $0.91 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.91 (Q1 2026), $0.24 (Q4 2025), and $1.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Oramed Pharmaceuticals | 151.47 Mn | 133.31 Mn | - | 0.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.91 |
| Dec 31, 2025 | 0.24 |
| Sep 30, 2025 | 1.13 |
| Jun 30, 2025 | 0.31 |
| Mar 31, 2025 | -0.19 |
| Dec 31, 2024 | -0.26 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | 0.22 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.33 |
| Sep 30, 2023 | -0.08 |
| Jun 30, 2023 | -0.03 |
| Mar 31, 2023 | -0.08 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -0.18 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.27 |
| Aug 31, 2021 | -0.78 |